• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Castle Biosciences Inc (NQ: CSTL )

    18.25 +0.77 (+4.41%)
    Streaming Delayed Price Updated: 11:41 AM EDT, Jul 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 120,409
    Open 17.98
    Bid (Size) 18.23 (1)
    Ask (Size) 18.26 (4)
    Prev. Close 17.48
    Today's Range 17.65 - 18.40
    52wk Range 12.07 - 25.91
    Shares Outstanding 25,167,365
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Castle Biosciences Honored with Top Workplaces Awards
    From Castle Biosciences Inc.
    Via Business Wire
    Top 5 Health Care Stocks That May Explode In July
    Via Benzinga

    Performance

    YTD
    -16.89%
    -16.89%
    1 Month
    -21.34%
    -21.34%
    3 Month
    -10.67%
    -10.67%
    6 Month
    -14.84%
    -14.84%
    1 Year
    -7.27%
    -7.27%

    More News

    Read More
    Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Castle Biosciences Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
    From Castle Biosciences Inc.
    Via Business Wire
    New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
    From Castle Biosciences Inc.
    Via Business Wire
    Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
    From Castle Biosciences Inc.
    Via Business Wire
    DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
    From Castle Biosciences Inc.
    Via Business Wire
    CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Castle Biosciences Reports First Quarter 2024 Results
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
    From Castle Biosciences Inc.
    Via Business Wire
    Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Announces Updates to its Board of Directors
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
    From Castle Biosciences Inc.
    Via Business Wire
    Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
    From Castle Biosciences Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.